article Open AccessTop 1% cited

Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials

Ophthalmology · 2013 · Vol. 120(10) · pp. 2013–2022

David M. Brown(Houston Methodist)Quan Dong Nguyen✉(University of Nebraska Medical Center)Dennis M. Marcus(Southeast Retina Center)David S. Boyer(Retina Vitreous Associates Medical Group)Sunil Patel(West Texas Retina Consultants)Leonard Feiner(Retina Associates)Patricio G. SchlottmannAmy Chen RundleJiameng ZhangRoman G. RubioAnthony P. AdamisJason S. EhrlichJ. Jill Hopkins

View via DOI Publisher page

Abstract

Proprietary or commercial disclosure may be found after the references.

Retinal Diseases and Treatments Retinal Imaging and Analysis Retinal and Optic ConditionsMedicineRanibizumabDiabetic macular edemaTerm (time)OphthalmologyClinical trialDiabetic retinopathyDiabetes mellitusSurgeryInternal medicine

MeSH terms

RanibizumabAdultDiabetic RetinopathyFemaleHumansMacular EdemaMaleVisual AcuityAngiogenesis InhibitorsIntravitreal InjectionsAntibodies, Monoclonal, Humanized

Citations

813

FWCI

68.14

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema